PolarityTE (PTEIQ) Competitors $0.14 0.00 (0.00%) As of 01/17/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsSEC FilingsTrends PTEIQ vs. THAR, CELZ, ALBT, FRTX, ARTL, SLRX, ATXI, PHIO, INM, and BPTHShould you be buying PolarityTE stock or one of its competitors? The main competitors of PolarityTE include Tharimmune (THAR), Creative Medical Technology (CELZ), Avalon GloboCare (ALBT), Fresh Tracks Therapeutics (FRTX), Artelo Biosciences (ARTL), Salarius Pharmaceuticals (SLRX), Avenue Therapeutics (ATXI), Phio Pharmaceuticals (PHIO), InMed Pharmaceuticals (INM), and Bio-Path (BPTH). These companies are all part of the "pharmaceutical products" industry. PolarityTE vs. Tharimmune Creative Medical Technology Avalon GloboCare Fresh Tracks Therapeutics Artelo Biosciences Salarius Pharmaceuticals Avenue Therapeutics Phio Pharmaceuticals InMed Pharmaceuticals Bio-Path Tharimmune (NASDAQ:THAR) and PolarityTE (NASDAQ:PTEIQ) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, media sentiment, risk, valuation, community ranking and earnings. Does the media favor THAR or PTEIQ? In the previous week, Tharimmune's average media sentiment score of 0.00 equaled PolarityTE'saverage media sentiment score. Company Overall Sentiment Tharimmune Neutral PolarityTE Neutral Which has more risk and volatility, THAR or PTEIQ? Tharimmune has a beta of 1.23, meaning that its stock price is 23% more volatile than the S&P 500. Comparatively, PolarityTE has a beta of 0.92, meaning that its stock price is 8% less volatile than the S&P 500. Do analysts rate THAR or PTEIQ? Tharimmune currently has a consensus target price of $17.00, suggesting a potential upside of 705.69%. Given Tharimmune's stronger consensus rating and higher possible upside, analysts clearly believe Tharimmune is more favorable than PolarityTE.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tharimmune 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50PolarityTE 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the MarketBeat Community believe in THAR or PTEIQ? Tharimmune received 2 more outperform votes than PolarityTE when rated by MarketBeat users. CompanyUnderperformOutperformTharimmuneOutperform Votes2100.00% Underperform VotesNo VotesPolarityTEN/AN/A Is THAR or PTEIQ more profitable? PolarityTE's return on equity of -106.08% beat Tharimmune's return on equity.Company Net Margins Return on Equity Return on Assets TharimmuneN/A -167.63% -130.18% PolarityTE N/A -106.08%-76.91% Which has better earnings and valuation, THAR or PTEIQ? PolarityTE has higher revenue and earnings than Tharimmune. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTharimmuneN/AN/A-$9.32MN/AN/APolarityTE$810K1.26-$7.83M-$3.28-0.04 Do insiders and institutionals have more ownership in THAR or PTEIQ? 1.2% of Tharimmune shares are held by institutional investors. Comparatively, 11.8% of PolarityTE shares are held by institutional investors. 2.4% of Tharimmune shares are held by company insiders. Comparatively, 5.4% of PolarityTE shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. SummaryTharimmune and PolarityTE tied by winning 6 of the 12 factors compared between the two stocks. Get PolarityTE News Delivered to You Automatically Sign up to receive the latest news and ratings for PTEIQ and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PTEIQ vs. The Competition Export to ExcelMetricPolarityTEBiotechnology IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.02M$177.42M$5.39B$9.13BDividend YieldN/A3.64%5.37%4.00%P/E Ratio-0.04131.1588.8317.53Price / Sales1.2619,225.091,282.2680.28Price / CashN/A13.0136.6032.90Price / Book0.069.234.964.69Net Income-$7.83M-$20.89M$117.89M$224.57M7 Day Performance24.64%0.40%2.75%3.33%1 Month Performance25.65%2.27%3.63%5.33%1 Year PerformanceN/A131.63%27.27%22.97% PolarityTE Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PTEIQPolarityTEN/A$0.14flatN/A+39.7%$1.02M$810,000.00-0.0460THARTharimmune2.946 of 5 stars$2.11+3.9%$17.00+705.7%-65.5%$4.08MN/A0.002CELZCreative Medical TechnologyN/A$2.33+2.6%N/A-46.3%$4.08M$10,000.00-0.615Positive NewsGap UpALBTAvalon GloboCare0.4507 of 5 stars$3.73+1.9%N/A-42.6%$4.07M$1.26M-0.195Positive NewsFRTXFresh Tracks TherapeuticsN/A$0.66flatN/A-32.7%$3.94M$8.01M-0.4720Gap DownARTLArtelo Biosciences3.0091 of 5 stars$1.20+4.7%$5.50+356.8%-17.9%$3.89MN/A-0.425Positive NewsSLRXSalarius Pharmaceuticals0.6759 of 5 stars$2.48-7.8%N/A-43.7%$3.88MN/A-0.3020Gap DownATXIAvenue Therapeutics2.9599 of 5 stars$1.85flatN/A-82.4%$3.80MN/A0.104Positive NewsHigh Trading VolumePHIOPhio Pharmaceuticals2.5106 of 5 stars$2.48-10.5%$36.00+1,351.6%-54.4%$3.70MN/A-0.2310Gap UpINMInMed Pharmaceuticals0.472 of 5 stars$5.05+2.0%N/A-31.0%$3.64M$4.60M-0.3610News CoveragePositive NewsTrading HaltedHigh Trading VolumeBPTHBio-Path1.4865 of 5 stars$0.84+2.7%$20.00+2,274.5%-89.9%$3.63MN/A0.0010Analyst ForecastNews Coverage Related Companies and Tools Related Companies Tharimmune Competitors Creative Medical Technology Competitors Avalon GloboCare Competitors Fresh Tracks Therapeutics Competitors Artelo Biosciences Competitors Salarius Pharmaceuticals Competitors Avenue Therapeutics Competitors Phio Pharmaceuticals Competitors InMed Pharmaceuticals Competitors Bio-Path Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:PTEIQ) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PolarityTE, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share PolarityTE With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
